NCT04635241

Inhaled Heparin for Hospitalised COVID-19 Patients

INHALEd Unfractionated HEParin for the Treatment of Hospitalised Patients With COVID-19 Meta-trial

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 485 (actual)
• Sponsor: Australian National University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This meta-trial is a prospective collaborative individual participant data meta-analysis of randomised controlled trials and early phase studies. Individual studies will be conducted in multiple countries, including Australia, the UK, the USA, Ireland, Argentina, Brazil and Egypt. Adult patients admitted to the hospital with confirmed SARS-CoV-2 infection, who do not require immediate mechanical ventilation, will be randomised to inhaled nebulised heparin or standard care for up to 21 days or until the patient has no respiratory symptoms. All studies will collect a minimum core dataset. The primary outcome for the meta-trial is the proportion of patients who receive invasive mechanical ventilation censored at day 28. Individual studies may have specific outcome measures in addition to the core set.

Conditions

• Covid19

Interventions

Type	Name	Description
DRUG	Unfractionated heparin	Inhaled nebulised 6 hourly

Timeline

• Start date: 2020-06-01
• Primary completion: 2023-11-01
• Completion: 2025-01-18
• First posted: 2020-11-19
• Last updated: 2025-06-17

Locations

5 sites across 3 countries: Argentina, Egypt, Indonesia